A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat's Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia [0.03%]
一项评估德斯鲁利单抗在非透析慢性肾脏病贫血患者中疗效和安全性的III期多中心、随机、双盲、安慰剂对照试验
Jie Ma,Xiangdong Yang,Xiaoyan Xiao et al.
Jie Ma et al.
Background: This phase III trial assessed desidustat's efficacy and safety compared with placebo for the treatment of anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD). ...
Contrast Media in Hospitalized Patients with Acute Kidney Injury - Renal and Clinical Outcomes [0.03%]
对比剂在急性肾损伤住院患者中的应用-肾脏和临床预后
Alon Bnaya,Razan Said,Linda Shavit
Alon Bnaya
Introduction: Acute kidney injury (AKI) is a common complication among hospitalized patients and is associated with substantial morbidity and mortality. Intravenous contrast media is frequently used in diagnostic imaging,...
Tolvaptan for autosomal dominant polycystic kidney disease: Real-world insights from a propensity score weighted retrospective cohort study [0.03%]
托伐普坦治疗常染色体显性多囊肾病：倾向得分加权回顾性队列研究的新见解
William R Marshall,Rajkumar Chinnadurai,Sharmilee Rengarajan et al.
William R Marshall et al.
Background: Tolvaptan slows disease progression of autosomal dominant polycystic kidney disease (ADPKD) in clinical trials, but real-world effectiveness remains uncertain. We evaluated the association between tolvaptan us...
Canagliflozin Reduces Proteinuria and Mitochondrial Fission in Membranous Nephropathy Rats via CAV1/PKA/DRP1 Inhibition [0.03%]
坎格列净通过抑制CAV1/PKA/DRP1减少膜性肾病大鼠蛋白尿和线粒体分裂
Xin Lv,Liling Cui,Hongyan Liu et al.
Xin Lv et al.
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated renoprotective effects in chronic kidney disease (CKD), but their therapeutic potential in membranous nephropathy (MN) remains unclear. In this study, analysis of the GEO...
Immune Deposits, Complement Activation and APOL1 Risk variants in Focal Segmental Glomerulosclerosis [0.03%]
免疫沉积物，补体活化和APOL1风险型在局灶节段性肾小球硬化中作用的研究
Yasar Caliskan,Virginie Royal,Stéphan Troyanov et al.
Yasar Caliskan et al.
Background: The role of immune deposits and complement activation in APOL1 mediated focal segmental glomerulosclerosis (FSGS) remains unclear. Using the CureGN cohort, we examined the associations between APOL1 renal risk...
Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial [0.03%]
低剂量利伐沙班治疗晚期慢性肾脏病患者心血管疾病研究方案的方法学文章：研究设计及基线特征（TRACK试验）
Sunil V Badve,Maha Al Ammari,Craig S Anderson et al.
Sunil V Badve et al.
Introduction: Patients with advanced stages of chronic kidney disease (CKD) and dialysis-dependent kidney failure are at a greater risk of cardiovascular events and mortality than those with early stages of CKD. There are...
Exercise Training And Progression Of Chronic Kidney Disease: The GFR-Exercise (GFR-Ex) Randomized Controlled Feasibility Study [0.03%]
运动锻炼对慢性肾脏病进展影响的可行性研究：GFR-运动(GFR-Ex)随机对照试验
Mark David Davies,Juliet Briggs,Abdulfattah Alejmi et al.
Mark David Davies et al.
Background: The GFR-Ex study assessed the feasibility of a 12-month exercise training program to attenuate the rate of decline in isotope-measured (mGFR) and estimated (eGFR) Glomerular Filtration Rate. ...
Authors' Response to "Urinary and Plasma KIM-1 in Chronic Kidney Disease: Prognostic Insights and Remaining Questions" [0.03%]
对《慢性肾脏病尿液和血浆KIM-1的预后启示及遗留问题》一文的作者回应
Thomas McDonnell,Magnus Söderberg,Maarten W Taal et al.
Thomas McDonnell et al.
A comparative analysis of left ventricular myocardial work in patients with diabetic and non‑diabetic kidney disease after peritoneal dialysis [0.03%]
糖尿病与非糖尿病肾病患者腹膜透析后左心室心肌做功的比较分析
Minjie Wan,Chunyan Yi,Yan Wang et al.
Minjie Wan et al.
Introduction: Initiation of dialysis encompasses new cardiovascular challenges on patients with end-stage kidney disease (ESKD). The prognostic value of assessment of left ventricular (LV) myocardial function in peritonea...
Efficacy and Safety of Finerenone in Patients with Idiopathic Membranous Nephropathy (IMN): A Multicenter, prospective-retrospective Real-World Study [0.03%]
用于特发性膜性肾病（IMN）患者的非奈利酮疗效和安全性的多中心前瞻性回顾性真实世界研究
Jia-Yi Li,Yu-Lin Zhu,Jian-Peng Zhang et al.
Jia-Yi Li et al.
Introduction: The efficacy and safety of finerenone in patients with idiopathic membranous nephropathy (IMN) remains unclear, especially given the need for additional supportive therapeutic options. ...